Intervention not reported
TXA given intravenously at a total dose of 2 g intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Aprotinin given intravenously · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
TXA given intra‐articularly at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision and intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin) Comparator…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 2 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Moderate
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of 2 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Moderate
Intervention not reported
TXA given intravenously and orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of greater than 3 g pre‐incision, intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Low
Smoking abstinence at longest · people who smoke
Cytisine may leads to higher smoking abstinence at longest compared with nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
It is very uncertain whether cytisine changes SAEs compared with nicotine replacement therapy (very low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiac SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with nicotine replacement therapy monotherapy (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline may leads to lower SAEs compared with nicotine replacement therapy monotherapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
1 finding from 1 review
Cardiac SAEs · people who smoke
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline showed no clear difference in smoking abstinence at longest compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review